07. November 2009
Zedira presents Open tTGTM at MEDICA in November 2009

02. November 2009
Meet Zedira at BIO-Europe in November 2009

04. August 2009
Zedira co-authors patient information about the implication of transglutaminase in celiac disease (Article published in "DZG Aktuell" in August 2009; article in German)

06. July 2009
Zedira develops drug against Celiac Disease (Article in Hessen-Biotech NEWS, July 2009; in German)

02. April 2009
Transglutaminase Newsletter April 2009

02. March 2009
Meet Zedira at 13th International Coeliac Disease Symposium 2009 in April 2009

01. March 2009
Meet Zedira at 4th Annual Huntington's Disease Therapeutics Conference in Cannes 2009 in April 2009

01. February 2009
Transglutaminase Newsletter February 2009 A complete range of antibodies available from Zedira!


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation